Explaining Alport syndrome-lessons from the adult nephrology clinic.

Holly Mabillard, Rebecca Ryan, Nik Tzoumas, Susie Gear, John A Sayer
{"title":"Explaining Alport syndrome-lessons from the adult nephrology clinic.","authors":"Holly Mabillard, Rebecca Ryan, Nik Tzoumas, Susie Gear, John A Sayer","doi":"10.1007/s44162-024-00036-z","DOIUrl":null,"url":null,"abstract":"<p><p>Alport syndrome is a genetic kidney disease that causes worsening of kidney function over time, often progressing to kidney failure. Some types of Alport syndrome cause other symptoms and signs, including hearing loss and eye abnormalities. Research now indicates that Alport syndrome (autosomal dominant inheritance) is the most common form. Alport syndrome can have X-linked or a rare form of autosomal recessive inheritance. Traditionally, a kidney biopsy was used to diagnose Alport syndrome, but genetic testing provides a more precise and less invasive means of diagnosis and reveals the underlying pattern of inheritance. At present, there are no specific curative treatments for Alport syndrome however there is a strong international effort in pursuit of future therapies. Currently, angiotensin-converting enzyme inhibitors (ACEi), or an angiotensin receptor blocker (ARB) if a patient cannot tolerate an ACEi, slow down the progression of kidney disease and can delay the onset of kidney failure by years. There are other potential treatments in research that potentially can help delay the onset of kidney issues. Early treatment of patients and identification of their at-risk relatives is a priority. People living with Alport syndrome and their doctors now benefit from an active international research community working on translating further treatments into clinical practice and providing up-to-date clinical guidelines.</p>","PeriodicalId":73925,"journal":{"name":"Journal of rare diseases (Berlin, Germany)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11088994/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of rare diseases (Berlin, Germany)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s44162-024-00036-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/13 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Alport syndrome is a genetic kidney disease that causes worsening of kidney function over time, often progressing to kidney failure. Some types of Alport syndrome cause other symptoms and signs, including hearing loss and eye abnormalities. Research now indicates that Alport syndrome (autosomal dominant inheritance) is the most common form. Alport syndrome can have X-linked or a rare form of autosomal recessive inheritance. Traditionally, a kidney biopsy was used to diagnose Alport syndrome, but genetic testing provides a more precise and less invasive means of diagnosis and reveals the underlying pattern of inheritance. At present, there are no specific curative treatments for Alport syndrome however there is a strong international effort in pursuit of future therapies. Currently, angiotensin-converting enzyme inhibitors (ACEi), or an angiotensin receptor blocker (ARB) if a patient cannot tolerate an ACEi, slow down the progression of kidney disease and can delay the onset of kidney failure by years. There are other potential treatments in research that potentially can help delay the onset of kidney issues. Early treatment of patients and identification of their at-risk relatives is a priority. People living with Alport syndrome and their doctors now benefit from an active international research community working on translating further treatments into clinical practice and providing up-to-date clinical guidelines.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
解释阿尔波特综合征--来自成人肾脏病诊所的启示。
阿尔波特综合征是一种遗传性肾脏疾病,会随着时间的推移导致肾功能恶化,通常会发展为肾衰竭。某些类型的阿尔波特综合征还会引起其他症状和体征,包括听力损失和眼睛异常。目前的研究表明,阿尔波特综合征(常染色体显性遗传)是最常见的类型。阿尔波特综合征可以是 X 连锁遗传,也可以是罕见的常染色体隐性遗传。传统上,肾活检被用来诊断阿尔波特综合征,但基因检测提供了一种更精确、创伤更小的诊断手段,并能揭示潜在的遗传模式。目前,阿尔波特综合征还没有特效的治疗方法,但国际上正在大力寻求未来的治疗方法。目前,血管紧张素转换酶抑制剂(ACEi)或血管紧张素受体阻滞剂(ARB)(如果患者不能耐受血管紧张素转换酶抑制剂)可减缓肾病的进展,并可将肾衰竭的发病时间推迟数年。研究中还有其他潜在的治疗方法,可能有助于延缓肾脏问题的发生。患者的早期治疗和高危亲属的识别是当务之急。现在,阿尔波特综合征患者和他们的医生都受益于一个活跃的国际研究团体,该团体致力于将进一步的治疗方法转化为临床实践,并提供最新的临床指南。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
FDrisk: development of a validated risk assessment tool for Fabry disease utilizing electronic health record data. Diverse retinal-kidney phenotypes associated with NPHP1 homozygous whole-gene deletions in patients with kidney failure. Explaining Alport syndrome-lessons from the adult nephrology clinic. Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland. Finerenone and other future therapeutic options for Alport syndrome
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1